WO2016035419A1 - 糖尿病性皮膚潰瘍治療のための多能性幹細胞 - Google Patents
糖尿病性皮膚潰瘍治療のための多能性幹細胞 Download PDFInfo
- Publication number
- WO2016035419A1 WO2016035419A1 PCT/JP2015/067789 JP2015067789W WO2016035419A1 WO 2016035419 A1 WO2016035419 A1 WO 2016035419A1 JP 2015067789 W JP2015067789 W JP 2015067789W WO 2016035419 A1 WO2016035419 A1 WO 2016035419A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- negative
- cell
- pluripotent stem
- cell preparation
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a cell preparation in regenerative medicine. More specifically, a cell preparation containing pluripotent stem cells effective for the repair and regeneration of skin tissue in skin ulcers including skin ulcers caused by diabetes, and a method for treating skin ulcers using the pluripotent stem cells About.
- Diabetes mellitus is a disease with a persistent hyperglycemic state, and is said to occur as a result of the action of various environmental factors and genetic factors. It is known that insulin is a major regulator of blood glucose, and hyperglycemia is caused by insulin deficiency or excessive factors that inhibit its action (eg, genetic predisposition, lack of exercise, obesity, stress, etc.). It has been. Diabetes is mainly caused by type I diabetes caused by a decrease in pancreatic insulin secretion function due to autoimmune diseases and the like, and a decrease in pancreatic insulin secretion function and insulin resistance due to pancreatic exhaustion associated with continuous high insulin secretion 2 Classified as type 2 diabetes.
- Non-patent Document 1 Non-patent Document 1
- the global market for anti-diabetic drugs is about 1 trillion yen in 2006. This is almost first in both market and population.
- leg complications cause the most damage. 40-70% of total lower limb amputations are associated with diabetes mellitus, and indeed 85% of all diabetic-related lower limb amputations occur following leg ulcers. In patients with diabetes mellitus, the risk of developing chronic skin ulcers such as leg ulcers increases with long-term complications. Ulceration occurs as a result of ischemia and / or neuropathy. Local tissue ischemia is a major cause of development for diabetic ulcers. Similar to macrovascular disease, patients with diabetes are exposed to further threats to skin perfusion associated with non-conductive arteries in the course of damage to microcirculatory control mechanisms called atherosclerosis and small vessel disease.
- neuropathy is a major complication of diabetes mellitus, with no well-established therapy for either symptomatic treatment or prevention of progressive decline in neurological function.
- the effects of peripheral neuropathy are complex.
- the mechanisms leading to neuronal damage in diabetes are still unresolved, but are said to be multifactorial, including genetic predisposition, metabolic and vascular abnormalities, and lack of perturbation of related growth factors.
- Adipose tissue-derived stromal cells are known as such cells, and are considered to have the ability to differentiate not only into adipocytes and blood vessels but also into various lineages (Non-Patent Documents 2 to 4).
- ASC Adipose tissue-derived stromal cells
- Non-Patent Documents 2 to 4 As an example using this ASC, there is a report of making a diabetic mouse and trying to cure an ischemic wound (Non-Patent Document 5).
- An example in which adipose tissue-derived regenerative cells are applied to clinical treatment of diabetic ulcers in the lower limbs of patients with peripheral arterial disorders has also been reported (Non-patent Document 6). However, the wound site has not been completely cured.
- iPS cells such as Patent Document 1
- a specific gene or a specific gene is identified in the dermal fibroblast fraction, which is a mesenchymal cell.
- iPS cells have a high tumorigenic ability, and therefore there is an extremely high hurdle for clinical application.
- pluripotent stem cells present in the mesenchymal cell fraction and expressing SSEA-3 (Stage-Specific Embryonic Antigen-3) as a surface antigen Differentiating Stress Enduring cells (Muse cells) are responsible for the pluripotency of the mesenchymal cell fraction, and have been found to be potentially applicable to disease treatment aimed at tissue regeneration (Patent Document 2; non-patent document 2) Patent Documents 9 to 12).
- SSEA-3 Serial-Specific Embryonic Antigen-3
- Patent Document 2 Non-patent document 2
- Patent Documents 9 to 12 Patent Documents 9 to 12
- An object of the present invention is to provide a new medical use using pluripotent stem cells (Muse cells) in regenerative medicine. More specifically, an object of the present invention is to provide a cell preparation for preventing and / or treating skin ulcer, which contains Muse cells.
- the present inventors have found that by administering Muse cells to diabetic skin ulcer mice to the affected skin ulcers, the Muse cells reconstruct and repair the skin tissue, resulting in ulcer healing. It came to complete.
- the present invention is as follows.
- a cell preparation for preventing and / or treating skin ulcer comprising SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue or cultured mesenchymal cells in a living body.
- the skin ulcer is selected from the group consisting of diabetic skin ulcer, decubitus ulcer, venous stasis ulcer, arterial ulcer, radiation ulcer, necrotizing fasciitis, and third degree burn ]
- the pluripotent stem cells are CD34 negative, CD117 negative, CD146 negative, CD271 negative, NG2 negative, vWF negative, Sox10 negative, Snai1 negative, Slug negative, Tyrp1 negative, and Dct negative.
- One or more pluripotent stem cells selected from the group consisting of epidermal keratinocytes, vascular endothelial cells, vascular pericytes, adipocytes, preadipocytes, dermal fibroblasts, and nerve sheath cells.
- the present invention relates to a skin ulcer by means of a skin tissue regeneration mechanism in which a Muse cell is administered to a subject suffering from a skin ulcer and the Muse cell is differentiated into a cell constituting the skin tissue in the affected part. It is possible to suppress the progress of the skin and repair the skin tissue.
- mice since the wound healing ability is originally high and the wound heals quickly, it is difficult to make the difference clear when evaluating the wound healing effect of the drug. Therefore, immunodeficient mice having diabetes, which is characterized by difficulty in wound healing, were used for evaluation of the wound healing effect.
- streptozotocin STZ
- STZ streptozotocin
- mice were used for evaluation of the wound healing effect.
- type I diabetes streptozotocin (STZ) was injected intraperitoneally into 5-week-old male SCID mice fasted for 24 hours. Three days after STZ administration (150 mg / kg), hyperglycemia (blood glucose> 300 mg / dl) was examined. When hyperglycemia was not observed, STZ administration (150 mg / kg) was performed again. A skin defect was created on the back of 9 week old DM-SCID mice.
- STZ streptozotocin
- MSCs are known to secrete growth factors required during the inflammatory and cell growth phases of wound healing. Therefore, the relative value of growth factor production in the Muse cell fraction and mesenchymal cell fraction (MSC) cultured for 48 hours under hypoxic (1% O 2 ) or normoxic (6% O 2 ) conditions was determined by ELISA. It was measured.
- the cytokines (growth factors) measured were HGF, SDF-1, PDGF-BB, VEGF, EGF, TGF- ⁇ , NGF- ⁇ , SCF, bFGF, and TNF- ⁇ .
- the Y axis shows the absorbance at 450 nm.
- the present invention relates to a cell preparation for preventing and / or treating skin ulcer, which contains SSEA-3-positive pluripotent stem cells (Muse cells).
- SSEA-3-positive pluripotent stem cells Muse cells
- the present invention aims at prevention and / or treatment of skin ulcer using a cell preparation containing SSEA-3-positive pluripotent stem cells (Muse cells).
- skin ulcer means an injury on the skin caused by a defect on the surface of the tissue (exposure of the dermis or subcutaneous tissue) usually caused by inflammation.
- Skin ulcers that can be prevented and / or treated by the cell preparation of the present invention include, but are not limited to, diabetic skin ulcers, pressure ulcers, venous stasis ulcers, arterial ulcers, radiation ulcers, necrotizing fasciitis, third Degree burns etc. are included.
- Diabetic skin ulcer is a very refractory skin ulcer caused by damage of vascular endothelial cells due to hyperglycemia, and examples thereof include diabetic foot ulcer and diabetic leg ulcer .
- decubitus is meant a chronic ulcer caused by pressure applied to an area of skin for an extended period of time. This type of wound is often referred to as bedsores.
- a “venous stasis ulcer” is caused by congestion of blood or other fluid from a defective vein.
- arterial ulcer is meant necrotic skin in an area surrounding an artery with poor blood flow.
- Rapid ulcer refers to an ulcer that occurs in irradiated skin.
- “Necrotizing fasciitis” refers to a soft tissue infection in which necrosis rapidly expands with the superficial fascia as the mainstay of bacterial infection. “Third-degree burn” refers to the entire dermis, the subcutaneous tissue, and burns. According to the present invention, the cell preparation of the present invention is particularly effective for the prevention and / or treatment of diabetic skin ulcer.
- Pluripotent stem cells The pluripotent stem cell used in the cell preparation of the present invention was found by Dezawa, one of the present inventors, in the human body and named “Muse (Multilineage-differentiating Stress Ending) cell”. It is. Muse cells can be obtained from bone tissue, skin tissue such as adipose tissue (Ogura, F., et al., Stem Cells Dev., Vol. 23, p. 717-728 (2014)) and dermal connective tissue. Also scattered in the connective tissue of each organ. In addition, this cell is a cell having the properties of both pluripotent stem cells and mesenchymal stem cells.
- the cell surface markers “SSEA-3 (Stage-specific embryonic antigen-3)” and “ Identified as "CD105” double positive.
- Muse cells or cell populations containing Muse cells can be separated from living tissues using, for example, these antigen markers as indicators.
- a cell population containing Muse cells can be concentrated by hypoxia or long-term stress caused by proteases such as trypsin and dyspase. Details such as a method for separating Muse cells, an identification method, and characteristics are disclosed in International Publication No. WO2011 / 007900. Also, as reported by Wakao et al. (2011, supra), when mesenchymal cells are cultured from bone marrow, skin, etc.
- SSEA-3 positive cells are CD105 It is known to be a positive cell. Accordingly, in the cell preparation of the present invention, when separating Muse cells from living mesenchymal tissue or cultured mesenchymal stem cells, the Muse cells can be purified and used simply with SSEA-3 as an antigen marker. .
- pluripotent stem cells separated from living mesenchymal tissue or cultured mesenchymal tissue using SSEA-3 as an antigen marker which can be used in cell preparations for treating skin ulcers (Muse cells) or a cell population containing Muse cells may be simply referred to as “SSEA-3 positive cells”.
- Muse cells or cell populations containing Muse cells can be obtained from living tissue (eg, using antibodies against the cell surface marker SSEA-3 alone, or both antibodies against SSEA-3 and CD105, respectively) , Mesenchymal tissue).
- living tissue eg, using antibodies against the cell surface marker SSEA-3 alone, or both antibodies against SSEA-3 and CD105, respectively
- Mesenchymal tissue e.g., Mesenchymal tissue.
- “living body” means a living body of a mammal. In the present invention, the living body does not include embryos whose developmental stage is earlier than the fertilized egg or blastocyst stage, but includes embryos in the developmental stage after the blastocyst stage including the fetus and blastocyst.
- Mammals include, but are not limited to, primates such as humans and monkeys, rodents such as mice, rats, rabbits, guinea pigs, cats, dogs, sheep, pigs, cows, horses, donkeys, goats, ferrets, etc. It is done. Muse cells used in the cell preparation of the present invention are clearly distinguished from embryonic stem cells (ES cells) and iPS cells in that they are separated from living tissues with a marker directly. “Mesenchymal tissue” refers to tissues such as bone, synovium, fat, blood, bone marrow, skeletal muscle, dermis, ligament, tendon, dental pulp, umbilical cord, umbilical cord blood, and tissues present in various organs.
- Muse cells can be obtained from bone marrow, skin, or adipose tissue.
- Muse cells may be separated from cultured mesenchymal cells such as fibroblasts and bone marrow mesenchymal stem cells using the separation means.
- the Muse cell used may be autologous to the recipient who receives the cell transplant, or may be another family.
- a Muse cell or a cell population containing a Muse cell can be separated from a living tissue using, for example, SSEA-3 positive and SSEA-3 and CD105 double positive as an index.
- SSEA-3 positive and SSEA-3 and CD105 double positive are known to include various types of stem cells and progenitor cells.
- Muse cells are not the same as these cells.
- Such stem cells and progenitor cells include skin-derived progenitor cells (SKP), neural crest stem cells (NCSC), melanoblast (MB), perivascular cells (PC), endothelial progenitor cells (EP), adipose-derived stem cells (ADSC). ).
- Muse cells can be isolated using “non-expression” of a marker unique to these cells as an index.
- Muse cells are CD34 (EP and ADSC markers), CD117 (c-kit) (MB markers), CD146 (PC and ADSC markers), CD271 (NGFR) (NCSC markers), NG2 (PC marker), vWF factor (von Willebrand factor) (EP marker), Sox10 (NCSC marker), Snai1 (SKP marker), Slug (SKP marker), Tyrp1 (MB marker), and At least one of 11 markers selected from the group consisting of Dct (MB marker), for example 2, 3, 4, 5, 6, 7, 8, 9, 10 The non-expression of individual or eleven markers can be separated into indicators.
- non-expression of CD117 and CD146 can be separated as an index
- non-expression of CD117, CD146, NG2, CD34, vWF and CD271 can be separated as an index
- the non-expression of 11 markers can be separated as an index.
- the Muse cell having the above characteristics used in the cell preparation of the present invention is as follows: (I) low or no telomerase activity; (Ii) has the ability to differentiate into cells of any germ layer of the three germ layers; It may have at least one property selected from the group consisting of (iii) showing no neoplastic growth; and (iv) having a self-renewal capability.
- the Muse cell used in the cell preparation of the present invention has all the above properties.
- telomerase activity is low or absent means that, for example, when telomerase activity is detected using TRAPEZE XL telomerase detection kit (Millipore), it is low or cannot be detected.
- “Low” telomerase activity means, for example, telomerase having a telomerase activity comparable to that of somatic human fibroblasts, or 1/5 or less, preferably 1/10 or less compared to Hela cells. It means having activity.
- the Muse cell has the ability to differentiate into three germ layers (endoderm, mesodermal, and ectoderm) in vitro and in vivo, for example, induction culture in vitro Can be differentiated into hepatocytes, nerve cells, skeletal muscle cells, smooth muscle cells, bone cells, fat cells and the like. In addition, when transplanted to the testis in vivo, it may show the ability to differentiate into three germ layers.
- Muse cells grow at a growth rate of about 1.3 days in suspension culture, but grow from 1 cell in suspension culture to form an embryoid body-like cell mass and stop growing in about 14 days. However, when these embryoid body-like cell masses are brought into an adhesion culture, cell proliferation is started again, and the proliferated cells spread from the cell masses. Furthermore, when transplanted to the testis, it has the property of not becoming cancerous for at least half a year.
- a Muse cell has self-renewal (self-replication) ability.
- self-renewal means that differentiation from cells contained in embryoid body-like cell clusters obtained by culturing in suspension culture from one Muse cell to trioderm cells can be confirmed, Bring the cells of embryoid body-like cell mass to suspension culture with one cell again to form the next generation embryoid body-like cell mass, from which again embryos in trioderm differentiation and suspension culture This means that a clot-like cell mass can be confirmed.
- the self-renewal may be repeated once or multiple times.
- the cell preparation of the present invention is not limited, but the Muse cell or the cell population containing Muse cell obtained in (1) above is treated with physiological saline or an appropriate buffer (for example, phosphorous). Acid buffered saline).
- physiological saline or an appropriate buffer for example, phosphorous. Acid buffered saline.
- the cells may be cultured before cell transplantation and grown until a predetermined cell concentration is obtained.
- Muse cells do not become tumors. Therefore, even if cells collected from living tissue remain undifferentiated, there is a possibility of canceration. Low and safe.
- the culture of the collected Muse cells is not particularly limited, but can be performed in a normal growth medium (for example, ⁇ -minimal essential medium ( ⁇ -MEM) containing 10% calf serum). More specifically, referring to the above International Publication No. WO2011 / 007900, in the culture and proliferation of Muse cells, a medium, additives (for example, antibiotics, serum) and the like are appropriately selected, and Muse cells at a predetermined concentration are selected. A solution containing can be prepared.
- a normal growth medium for example, ⁇ -minimal essential medium ( ⁇ -MEM) containing 10% calf serum.
- the cell preparation of the present invention When the cell preparation of the present invention is administered to a human subject, about several ml of bone marrow fluid is collected from human iliac bone, and for example, bone marrow mesenchymal stem cells are cultured as adherent cells from the bone marrow fluid and effective.
- the Muse cells can be isolated using the SSEA-3 antigen marker as an indicator, and autologous or other Muse cells can be prepared as cell preparations.
- a cell population containing Muse cells can be concentrated and prepared as a cell preparation by stress such as hypoxia or protease.
- the cells are cultured and expanded until an effective therapeutic amount is reached, and then autologous Muse cells can be prepared as a cell preparation.
- Muse cells when using Muse cells in cell preparations, dimethyl sulfoxide (DMSO), serum albumin, etc. are included in the cell preparations to protect the cells, and antibiotics, etc., are included in the cell preparations to prevent bacterial contamination and growth. May be.
- DMSO dimethyl sulfoxide
- other pharmaceutically acceptable ingredients for example, carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, preservatives, physiological saline, etc.
- Cells or components other than Muse cells contained in mesenchymal stem cells may be contained in the cell preparation.
- Muse cells can also be used as pharmaceutical compositions containing various additives.
- the number of Muse cells contained in the above-prepared cell preparation is determined based on the sex, age, weight, and affected area of the subject so that a desired effect (for example, skin tissue reconstruction) can be obtained in the treatment of skin ulcer. It can be appropriately adjusted in consideration of the state, the state of the cells used, and the like.
- various effects of Muse cell transplantation were examined on an immunodeficient diabetic mouse model prepared by administration of streptozotocin (STZ). By administering SSEA3 positive cells to the affected area at 1.0 ⁇ 10 5 cells / head to about 20-30 g of SCID mice, a very excellent effect was obtained.
- the cell preparation of the present invention can be used a plurality of times (for example, 2 to 10 times) at appropriate intervals (for example, twice a day, once a day, once a week) until a desired therapeutic effect is obtained. 2 times, once a week, once every two weeks, once a month, once every two months, once every three months, once every six months) Also good.
- the therapeutically effective dose is preferably, for example, 1 ⁇ 10 3 cells to 1 ⁇ 10 7 cells per individual and 1 to 10 doses.
- the total dose in one individual is not limited, but 1 ⁇ 10 3 cells to 1 ⁇ 10 8 cells, 1 ⁇ 10 4 cells to 5 ⁇ 10 7 cells, 2 ⁇ 10 4 cells to 2 ⁇ 10 7 cells, 5 ⁇ Examples include 10 4 cells to 5 ⁇ 10 6 cells, 1 ⁇ 10 5 cells to 1 ⁇ 10 6 cells, and the like.
- a mouse diabetic skin ulcer model can be constructed and used. it can.
- the mice used as the model are not limited, but generally include SCID mice and Balb / c mice.
- a diabetic skin ulcer model can be created by intraperitoneally administering streptozotocin (STZ) to these mice.
- STZ is a derivative of glucose and is used to damage pancreatic ⁇ cells and cause diabetes in animals.
- the dosage of STZ is preferably 150 mg / kg per dose, and may be dosed multiple times.
- the cell preparation of the present invention is a human-derived Muse cell, it has a heterogeneous relationship with the mouse to which the preparation is administered.
- an immunosuppressant such as cyclosporine
- mesenchymal cells which are the population of Muse cells, originally have strong immunosuppression, and Muse cells also have the same action. Therefore, in the present invention, it is not necessary to use an immunosuppressive agent in a mouse model that does not use an immunosuppressive agent other than SCID mice.
- the cell preparation of the present invention can treat a patient's skin ulcer and reconstruct normal skin.
- “reconstruct normal skin” means a state in which an affected part having a skin ulcer has been wound-healed and completely cured.
- the reconstructed skin state is preferably a state in which the entire surface is covered with epithelial keratinocytes, and epithelialization is completed.
- a dermis having a sufficient thickness is constructed under the epithelium. More preferably, skin appendages such as sweat glands and / or hair follicles are being regenerated.
- various cytokines can be secreted from Muse cells by culturing Muse cells in a hypoxic state (for example, oxygen concentration of 1%) (see Example 3). Therefore, according to the present invention, there is provided a method for increasing the ability to produce at least one cytokine of VEGF, EGF, PDGF-BB, NGF- ⁇ , SCF, TNF- ⁇ , bFGF, and TGF- ⁇ .
- the stromal vascular fraction (SVF) containing adipose-derived stem cells / stromal cells (ASC) was previously described (Yoshimura K, et al., J. Cell Physiol., Vol. 208, p. 64-76). (2006)) and isolated from aspirated fat.
- a fat-derived stromal / stem cell-containing (ASC) cell pellet (corresponding to SVF) is cultured in a dish containing Dulbecco's modified Eagle's medium (DMEM; Nissan, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS) did.
- DMEM Dulbecco's modified Eagle's medium
- the proliferated hASC was subcultured using the same medium.
- the second passage hASC was harvested with 0.25% trypsin containing 2 mM EDTA at 37 ° C. for 5 minutes and used to isolate Muse cells.
- MACS mesenchymal cell fraction
- Example 2 Preparation of an immunodeficient diabetic mouse model
- SCID severe combined immunodeficient
- C.B17 / Icr-scid, scid / scid was obtained from CLEA Japan, Inc. (Tokyo, Japan). All animal experiments were conducted with approval from the Institutional Animal Care and Use Committee at the University of Tokyo. After SCID mice are fasted for 24 hours, citrate buffered saline (pH 4.5) containing newly prepared streptozotocin (STZ; 150 mg / kg, Sigma-Aldrich, St. Louis, MO) is injected intraperitoneally. did.
- Blood glucose levels were measured using a glucometer and test strip (Glucose Pilot, Aventir Biotech LLC, Carlsbad, Calif.) 3 days after STZ injection. Mice were considered diabetic (DM) if blood glucose levels were above 300 mg / dl. Mice that did not show hyperglycemia (> 300 mg / dl) were given a second STZ injection (150 mg / kg) and blood glucose levels were monitored 3 days later (FIG. 1A).
- mice were individually anesthetized by intraperitoneal injection of pentobarbital (65 mg / kg). Two full-thickness skin wounds (diameter 6 mm in diameter) penetrating the dermal muscle layer using a disinfected circular biopsy punch (Kai Industries Co., Tokyo, Japan) after hair removal using an electric trimmer and hair removal cream ) was created on the back of the mouse.
- mice Five experimental groups: wild-type mice, non-DM-SCID mice, DM-derived SCID mice, DM-induced SCID mice treated with the Muse cell population, and DM-induced SCID mice treated with the mesenchymal cell fraction (MSC). Got ready. Six mice in each group were used. Muse cells (1.0 ⁇ 10 5 cells / mouse) were mixed with 0.1 ml of crosslinked hyaluronic acid (Restylane, Q-MED, Uppsala, Sweden) and then injected subcutaneously around the wound. Macroscopically, the time to wound closure (days to complete epithelial regeneration) was examined. Wounds were taken sequentially on days 0, 3, 7, 10, and 14 using a conventional digital camera (IXY Digital 90, Canon, Tokyo, Japan). Photos were evaluated using image analysis software (Photoshop CS6, Adobe Systems, San Jose, Calif.) And the wound area was measured.
- image analysis software Photoshop CS6, Adobe Systems, San Jose, Calif.
- Example 3 Cytokine production assay (ELISA method) MSCs are known to secrete growth factors (eg, PDGF, bFGF, TGF- ⁇ , EGF, etc.) required during the inflammatory and cell growth phases of wound healing (Maxson, S., et al. , Stem Cells Transl. Med., Vol.1, p.142-149 (2012)). Therefore, Muse cell populations and MSCs were cultured in vitro under hypoxic conditions and normoxic conditions, and cytokines secreted into the culture medium were examined. The experiment was performed as follows.
- growth factors eg, PDGF, bFGF, TGF- ⁇ , EGF, etc.
- HGF hepatocyte growth factor
- SDF-1 stromal cell derived factor 1
- VEGF vascular endothelial growth factor
- EGF epidermal growth factor
- PDGF-BB Platelet derived growth factor
- NGF- ⁇ nerve growth factor- ⁇
- SCF stem cell factor
- TGF- ⁇ tumor necrosis factor- ⁇
- TGF- ⁇ transforming growth factor- ⁇
- FIG. 2 shows the results of comparing the concentration of cytokines in the culture medium after 48 hours after adhesion culture of Muse cell population and MSC in normoxic (6% O 2 ) or hypoxic (1% O 2 ) conditions.
- the Muse cell population released higher amounts of EGF, PDGF-BB, NGF- ⁇ , SCF, TNF- ⁇ , bFGF, and TGF- ⁇ compared to MSCs cultured at the same oxygen tension.
- the concentrations of VEGF, EGF, PDGF-BB, NGF- ⁇ , SCF, TNF- ⁇ , bFGF, and TGF- ⁇ were higher in hypoxic conditions than in normoxic conditions, especially in the Muse cell population. .
- Example 4 Wound healing streptozotocin (STZ) in DM-SCID mice injured pancreatic ⁇ cells and induced type I DM, but doses and methods of STZ have been reported previously (Schmidt, RE; , Et al., Am. J. Pathol., Vol.163, p.2077-2091 (2003), Lee, RH, et al., Proc.Natl.Acad.Sci.USA., Vol. P. 17438-17443 (2006); Schmidt, RE, et al., Exp. Neurol., Vol. 209, p. 161-170 (2008)). When 200 mg / kg STZ was administered, SCID mice often died within 1 week of administration due to severe weight loss and metabolic abnormalities.
- DM-derived SCID mice successfully prepared by 1 (9/29 mice; 31.0%) or 2 (13/29 mice; 44.8%) STZ injections was used for wound healing experiments for 30 days after the final STZ injection.
- the wound sizes of DM-SCID mice treated with Muse cells and MSC were 51.05 ⁇ 7.2% and 74.0 ⁇ 6.6%, respectively (P ⁇ 0.0001).
- DM-SCID mice treated with Muse cells promoted wound healing and appeared to be comparable to those in the WT group.
- Example 5 Histological analysis Mouse skin samples were embedded in OCT compounds (Sakura Finetek, Tokyo, Japan), frozen in liquid nitrogen and stored at -80 ° C until sectioning. Cryosections (8 ⁇ m) were placed on slides, dried at room temperature for 20 minutes, fixed with 4% paraformaldehyde (in PBS) for 1 minute, and washed with PBS for 5 minutes. Slides were stained with hematoxylin and eosin (H & E) and processed for immunohistochemical analysis.
- OCT compounds Sakura Finetek, Tokyo, Japan
- -Diaminobenzidine Visualized by peroxidase reaction with tetrahydrochloride (DAB) Cryosections were incubated with the following primary antibodies for confocal laser microscopy: mouse anti-human mitochondria (1: 100 dilution, Abcam), rabbit anti-human 58K Golgi protein, rabbit anti-human-CK14 (1: 200 dilution, Abcam) or goat anti-human platelet endothelial cell binding molecule-1 (PECAM-1; 1:50 dilution, Santa Cruz Biotechnology, Santa Cruz, CA).
- Sections were incubated with the following secondary antibodies: donkey anti-mouse IgG-Alexa 488, donkey anti-rabbit IgG-Alexa 680, or rabbit anti-goat IgG-Alexa 488 (all 1: 500 dilution, Invit ogen, Carlsbad, CA). Nuclei were counterstained with DAPI, a confocal microscope (C1si Nikon, Nikon, Tokyo, Japan) were tested using.
- the cell preparation of the present invention can be applied to the skin ulcer affected part of a diabetic skin ulcer mouse model, whereby the skin tissue can be reconstructed and repaired, and can be applied to the treatment of diabetic skin ulcer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]生体の間葉系組織又は培養間葉系細胞から分離されたSSEA-3陽性の多能性幹細胞を含む、皮膚潰瘍を予防及び/又は治療するための細胞製剤。
[2]外部ストレス刺激によりSSEA-3陽性の多能性幹細胞が、濃縮された細胞画分を含む、上記[1]に記載の細胞製剤。
[3]前記皮膚潰瘍が、糖尿病性皮膚潰瘍、褥瘡性潰瘍、静脈うっ血潰瘍、動脈性潰瘍、放射線潰瘍、壊死性筋膜炎、及び第3度熱傷からなる群から選択される、上記[1]及び[2]に記載の細胞製剤。
[4]前記多能性幹細胞が、CD105陽性である、上記[1]~[3]に記載の細胞製剤。
[5]前記多能性幹細胞が、CD117陰性及びCD146陰性である、上記[1]~[4]に記載の細胞製剤。
[6]前記多能性幹細胞が、CD117陰性、CD146陰性、NG2陰性、CD34陰性、vWF陰性、及びCD271陰性である、上記[1]~[5]に記載の細胞製剤。
[7]前記多能性幹細胞が、CD34陰性、CD117陰性、CD146陰性、CD271陰性、NG2陰性、vWF陰性、Sox10陰性、Snai1陰性、Slug陰性、Tyrp1陰性、及びDct陰性である、上記[1]~[6]に記載の細胞製剤。
[8]前記多能性幹細胞が、以下の性質の全てを有する多能性幹細胞である、上記[1]~[7]に記載の細胞製剤:
(i)テロメラーゼ活性が低いか又は無い;
(ii)三胚葉のいずれの胚葉の細胞に分化する能力を持つ;
(iii)腫瘍性増殖を示さない;及び
(iv)セルフリニューアル能を持つ。
[9]前記多能性幹細胞が、表皮角化細胞、血管内皮細胞、血管周皮細胞、脂肪細胞、脂肪前駆細胞、皮膚線維芽細胞、及び神経鞘細胞からなる群から選択される1つ以上の細胞に分化する能力を有する、上記[1]~[8]に記載の細胞製剤。
本発明は、SSEA-3陽性の多能性幹細胞(Muse細胞)を含む細胞製剤を用いて、皮膚潰瘍の予防及び/又は治療を目指す。ここで、「皮膚潰瘍」とは、通常は炎症による組織表面の欠損(真皮又は皮下組織の露出)が原因の皮膚上の傷害を意味する。本発明の細胞製剤によって予防及び/又は治療可能な皮膚潰瘍には、限定されないが、糖尿病性皮膚潰瘍、褥瘡性潰瘍、静脈うっ血潰瘍、動脈性潰瘍、放射線潰瘍、壊死性筋膜炎、第3度熱傷などが含まれる。「糖尿病性皮膚潰瘍」とは、高血糖による血管内皮細胞の損傷に起因した、非常に難治性の皮膚潰瘍であって、例えば、糖尿病性足部潰瘍、糖尿病性下腿部潰瘍が例示される。「褥瘡」とは、皮膚の領域に長期間かけられた圧が原因となった慢性潰瘍を意味する。この種の創傷はしばしば床ずれとも呼ばれる。「静脈うっ血潰瘍」は、欠陥静脈からの血液又は他の液体のうっ血によって起こる。「動脈性潰瘍」とは、血流が悪い動脈周囲の領域における壊死皮膚を意味する。「放射線潰瘍」とは、放射線照射を受けた皮膚に生じる潰瘍を指す。「壊死性筋膜炎」とは、浅層筋膜を細菌感染の主座として急速に壊死が拡大する軟部組織感染症を指す。また、「第3度熱傷」とは、真皮全層、皮下組織にまで及び火傷を意味する。本発明によれば、本発明の細胞製剤は、特に糖尿病性皮膚潰瘍の予防及び/又は治療に有効である。
(1)多能性幹細胞(Muse細胞)
本発明の細胞製剤に使用される多能性幹細胞は、本発明者らの一人である出澤が、ヒト生体内にその存在を見出し、「Muse(Multilineage-differentiating Stress Enduring)細胞」と命名した細胞である。Muse細胞は、骨髄液、脂肪組織(Ogura,F.,et al.,Stem Cells Dev.,Vol.23,p.717-728(2014))や真皮結合組織等の皮膚組織から得ることができ、各臓器の結合組織にも散在する。また、この細胞は、多能性幹細胞と間葉系幹細胞の両方の性質を有する細胞であり、例えば、それぞれの細胞表面マーカーである「SSEA-3(Stage-specific embryonic antigen-3)」と「CD105」のダブル陽性として同定される。したがって、Muse細胞又はMuse細胞を含む細胞集団は、例えば、これらの抗原マーカーを指標として生体組織から分離することができる。また、低酸素、又はトリプシンやジズパーゼ等のプロテアーゼによる長時間のストレスによりMuse細胞を含む細胞集団を濃縮することができる。Muse細胞の分離法、同定法、及び特徴などの詳細は、国際公開第WO2011/007900号に開示されている。また、Wakaoら(2011、上述)によって報告されているように、骨髄、皮膚などから間葉系細胞を培養し、それをMuse細胞の母集団として用いる場合、SSEA-3陽性細胞の全てがCD105陽性細胞であることが分かっている。したがって、本発明における細胞製剤においては、生体の間葉系組織又は培養間葉系幹細胞からMuse細胞を分離する場合は、単にSSEA-3を抗原マーカーとしてMuse細胞を精製し、使用することができる。なお、本明細書においては、皮膚潰瘍を治療するための細胞製剤において使用され得る、SSEA-3を抗原マーカーとして、生体の間葉系組織又は培養間葉系組織から分離された多能性幹細胞(Muse細胞)又はMuse細胞を含む細胞集団を単に「SSEA-3陽性細胞」と記載することがある。
(i)テロメラーゼ活性が低いか又は無い;
(ii)三胚葉のいずれの胚葉の細胞に分化する能力を持つ;
(iii)腫瘍性増殖を示さない;及び
(iv)セルフリニューアル能を持つ
からなる群から選択される少なくとも1つの性質を有してもよい。本発明の一局面では、本発明の細胞製剤に使用されるMuse細胞は、上記性質を全て有する。ここで、上記(i)について、「テロメラーゼ活性が低いか又は無い」とは、例えば、TRAPEZE XL telomerase detection kit(Millipore社)を用いてテロメラーゼ活性を検出した場合に、低いか又は検出できないことをいう。テロメラーゼ活性が「低い」とは、例えば、体細胞であるヒト線維芽細胞と同程度のテロメラーゼ活性を有しているか、又はHela細胞に比べて1/5以下、好ましくは1/10以下のテロメラーゼ活性を有していることをいう。上記(ii)について、Muse細胞は、in vitro及びin vivoにおいて、三胚葉(内胚葉系、中胚葉系、及び外胚葉系)に分化する能力を有し、例えば、in vitroで誘導培養することにより、肝細胞、神経細胞、骨格筋細胞、平滑筋細胞、骨細胞、脂肪細胞等に分化し得る。また、in vivoで精巣に移植した場合にも三胚葉に分化する能力を示す場合がある。さらに、静注により生体に移植することで損傷を受けた臓器(心臓、皮膚、脊髄、肝、筋肉等)に遊走及び生着し、組織に応じた細胞に分化する能力を有する。上記(iii)について、Muse細胞は、浮遊培養では増殖速度約1.3日で増殖するが、浮遊培養では1細胞から増殖し、胚様体様細胞塊を作り14日間程度で増殖が止まる、という性質を有するが、これらの胚様体様細胞塊を接着培養に持っていくと、再び細胞増殖が開始され、細胞塊から増殖した細胞が広がっていく。さらに精巣に移植した場合、少なくとも半年間は癌化しないという性質を有する。また、上記(iv)について、Muse細胞は、セルフリニューアル(自己複製)能を有する。ここで、「セルフリニューアル」とは、1個のMuse細胞から浮遊培養で培養することにより得られる胚様体様細胞塊に含まれる細胞から3胚葉性の細胞への分化が確認できると同時に、胚様体様細胞塊の細胞を再び1細胞で浮遊培養に持っていくことにより、次の世代の胚様体様細胞塊を形成させ、そこから再び3胚葉性の分化と浮遊培養での胚様体様細胞塊が確認できることをいう。セルフリニューアルは1回又は複数回のサイクルを繰り返せばよい。
本発明の細胞製剤は、限定されないが、上記(1)で得られたMuse細胞又はMuse細胞を含む細胞集団を生理食塩水や適切な緩衝液(例えば、リン酸緩衝生理食塩水)に懸濁させることによって得られる。この場合、自家又は他家の組織から分離したMuse細胞数が少ない場合には、細胞移植前に細胞を培養して、所定の細胞濃度が得られるまで増殖させてもよい。なお、すでに報告されているように(国際公開第WO2011/007900号)、Muse細胞は、腫瘍化しないため、生体組織から回収した細胞が未分化のまま含まれていても癌化の可能性が低く安全である。また、回収したMuse細胞の培養は、特に限定されないが、通常の増殖培地(例えば、10%仔牛血清を含むα-最少必須培地(α-MEM))において行うことができる。より詳しくは、上記国際公開第WO2011/007900号を参照して、Muse細胞の培養及び増殖において、適宜、培地、添加物(例えば、抗生物質、血清)等を選択し、所定濃度のMuse細胞を含む溶液を調製することができる。ヒト対象に本発明の細胞製剤を投与する場合には、ヒトの腸骨から数ml程度の骨髄液を採取し、例えば、骨髄液からの接着細胞として骨髄間葉系幹細胞を培養して有効な治療量のMuse細胞を分離できる細胞量に達するまで増やした後、Muse細胞をSSEA-3の抗原マーカーを指標として分離し、自家又は他家のMuse細胞を細胞製剤として調製することができる。または、低酸素やプロテアーゼ等のストレスによりMuse細胞を含む細胞集団を濃縮して細胞製剤として調製することができる。あるいは、例えば、Muse細胞をSSEA-3の抗原マーカーを指標として分離後、有効な治療量に達するまで細胞を培養して増やした後、自家のMuse細胞を細胞製剤として調製することができる。
本明細書においては、本発明の細胞製剤による皮膚潰瘍の治療効果を検討するためにマウス糖尿病性皮膚潰瘍モデルを構築し、使用することができる。該モデルとして使用されるマウスには、限定されないが、一般的に、SCIDマウス、Balb/cマウスが挙げられる。糖尿病性皮膚潰瘍モデルは、これらのマウスにストレプトゾトシン(STZ)を腹腔内投与することによって作製され得る。STZは、グルコースの誘導体であって、膵臓のβ細胞に損傷を与え、動物に糖尿病を発症させるために使用されている。本発明によれば、STZの投薬量は、1回あたり、好ましくは150mg/kgであり、複数回投薬されてもよい。
(1)ヒト組織のサンプリング及び細胞単離
東京大学医学系研究科の倫理委員会の承認を得て、インフォームドコンセントを得た5人の女性非肥満患者(年齢=26.6±8.7、BMI=21.5±2.0)の腹部及び/又は太ももから脂肪吸引手術により脂肪吸引物を入手した。脂肪由来幹細胞/間質細胞(ASC)を含む間質血管画分(SVF)は、既述のように(Yoshimura K,et al.,J.Cell Physiol.,Vol.208,p.64-76(2006)参照)、吸引した脂肪から単離した。簡潔には、吸引脂肪組織をPBSで洗浄し、シェーカー上、37℃で30分間、0.075%のコラゲナーゼを含有するPBS中で消化した。成熟脂肪細胞及び結合組織を遠心分離によってペレットから分離した。細胞ペレットを再懸濁し、100μm、70μm、及び40μmのメッシュでろ過し、溶血した。脂肪由来間質/幹細胞を含有する(ASC)細胞ペレット(SVFに相当)を、10%ウシ胎児血清(FBS)を補充したダルベッコ改変イーグル培地(DMEM;Nissui,Tokyo,Japan)を含むディッシュで培養した。培養から約2週間後、増殖したhASCを同培地を用いて継代培養した。二代目の継代培養hASCを2mMのEDTAを含有する0.25%トリプシンを用いて、37℃で5分間かけて回収し、Muse細胞の単離に使用した。
SSEA-3陽性のMuse細胞を回収するために、磁気活性型細胞ソーティング装置(magnetic-activated cell sorting(MACS))(autoMACS,Miltenyi Biotec,Bergisch Gladbach,Germany)を使用した。Muse細胞はその表面にSSEA-3を発現するので、フィコエリトリン(PE)(1:3希釈、Miltenyi Biotec)及び抗PEマイクロビーズ(1:2希釈、Miltenyi Biotec)と結合した抗SSEA-3抗体をMuse細胞のMACS分離に用いた。マイクロビーズで標識した標的細胞を、磁場内でトラップし、その後陽性画分として回収した。磁気カラムに結合しなかった細胞溶液は、陰性画分として回収した。Muse細胞をより良く精製するために、非常に遅い速度で細胞溶液を2回磁気カラムにかけるMACSプログラムを使用した。得られた陽性細胞画分をMuse細胞集団とし、一方、陰性細胞画分を間葉系細胞画分(MSC)として、以下の実施例において使用した。
5週齢の雄性重症複合免疫不全(SCID)マウス(C.B17/Icr-scid,scid/scid)をCLEA Japan,Inc.(Tokyo,Japan)から購入した。全ての動物実験は、東京大学の施設内動物管理使用委員会からの承認を得て実施した。SCIDマウスを24時間絶食させた後に、新たに調製したストレプトゾトシン(STZ;150mg/kg,Sigma-Aldrich,St.Louis,MO)を含有するクエン酸緩衝食塩水(pH4.5)を腹腔内に注射した。血中グルコースレベルを、STZ注射後3日目に、グルコメーター及び試験片(Glucose Pilot,Aventir Biotech LLC,Carlsbad,CA)を用いて測定した。血中グルコースレベルが300mg/dl超であると、マウスは糖尿病(DM)を有するとした。高血糖(>300mg/dl)を示さなかったマウスには、二回目のSTZ注射(150mg/kg)を行い、その3日後に血中グルコースレベルをモニターした(図1A)。
MSCは、創傷治癒における炎症期及び細胞増殖期に必要とされる増殖因子(例えば、PDGF、bFGF、TGF-β、EGFなど)を分泌することが知られている(Maxson,S.,et al.,Stem Cells Transl.Med.,Vol.1,p.142-149(2012))。そこで、インビトロにおいて、低酸素条件下及び正常酸素条件下で、Muse細胞集団及びMSCを培養し、培養液中に分泌されるサイトカインについて検討した。実験を以下の通りに行った。4.0×105個のMuse細胞集団及びMSCを60mmディッシュに播種し、血清不含有のDMEM中で、低酸素(1%O2)又は正常酸素(6%O2)条件において培養した。48時間後、培養培地を回収し、0.22μmフィルター(Millex-GV filter,Millipore,Billerica,MA)を用いてろ過した。肝細胞増殖因子(HGF)及び間質細胞由来因子1(SDF-1)(両者ともR&D Systems,Minneapolis,MN)についてはELISAキット、並びに血管内皮増殖因子(VEGF)、上皮成長因子(EGF)、血小板由来成長因子(PDGF-BB)、神経成長因子-β(NGF-β)、幹細胞因子(SCF)、腫瘍壊死因子-α(TNF-α)、塩基性線維芽細胞成長因子(bFGF)、及び形質転換増殖因子-β(TGF-β)(Signosis #EA-1101,Santa Clara,CA)についてはサイトカインアレイキットを用いて、分泌されたサイトカイン量を比較検討した。吸光度を、分光光度法により無限マイクロプレートリーダー(M1000,Tecan Group,Mannedorf,Switzerland)を用いて450nmで測定した。
ストレプトゾトシン(STZ)は、膵臓β細胞を損傷し、I型DMを誘導したが、STZの投与用量及び方法がこれまでの報告(Schmidt,R.E.,et al.,Am.J.Pathol.,Vol.163,p.2077-2091(2003);Lee,R.H.,et al.,Proc.Natl.Acad.Sci.USA.,Vol.103,p.17438-17443(2006);Schmidt,R.E.,et al.,Exp.Neurol.,Vol.209,p.161-170(2008)参照)と異なっていた。200mg/kgのSTZを投与すると、SCIDマウスは、重度の体重減少及び代謝異常により投与の1週間以内に死亡することが多かった。しかしながら、絶食から24時間後のSCIDマウスに150mg/kgのSTZを注射すると、比較的一貫して高血糖を誘導することができ、DM状態(>300mg/dlの血中グルコース)が30日超続いた(図1B)。1回(29匹中9匹のマウス;31.0%)又は2回(29匹中13匹のマウス;44.8%)のSTZ注射による調製に成功したDM誘導SCIDマウス(DM-SCID)を、最終STZ注射から30日間、創傷治癒実験に用いた。
マウス皮膚試料は、OCT化合物(Sakura Finetek,Tokyo,Japan)に包埋し、液体窒素中で凍結し、切片化するまで-80℃で保存した。凍結切片(8μm)をスライド上に置き、20分間室温で乾燥させ、1分間、4%パラホルムアルデヒド(PBS中)で固定し、PBSで5分間洗浄した。スライドをヘマトキシリン及びエオシン(H&E)で染色し、免疫組織化学分析用に処理した。
Claims (9)
- 生体の間葉系組織又は培養間葉系細胞から分離されたSSEA-3陽性の多能性幹細胞を含む、皮膚潰瘍を予防及び/又は治療するための細胞製剤。
- 外部ストレス刺激によりSSEA-3陽性の多能性幹細胞が、濃縮された細胞画分を含む、請求項1に記載の細胞製剤。
- 前記皮膚潰瘍が、糖尿病性皮膚潰瘍、褥瘡性潰瘍、静脈うっ血潰瘍、動脈性潰瘍、放射線潰瘍、壊死性筋膜炎、及び第3度熱傷からなる群から選択される、請求項1又は2に記載の細胞製剤。
- 前記多能性幹細胞が、CD105陽性である、請求項1~3のいずれか1項に記載の細胞製剤。
- 前記多能性幹細胞が、CD117陰性及びCD146陰性である、請求項1~4のいずれか1項に記載の細胞製剤。
- 前記多能性幹細胞が、CD117陰性、CD146陰性、NG2陰性、CD34陰性、vWF陰性、及びCD271陰性である、請求項1~5のいずれか1項に記載の細胞製剤。
- 前記多能性幹細胞が、CD34陰性、CD117陰性、CD146陰性、CD271陰性、NG2陰性、vWF陰性、Sox10陰性、Snai1陰性、Slug陰性、Tyrp1陰性、及びDct陰性である、請求項1~6のいずれか1項に記載の細胞製剤。
- 前記多能性幹細胞が、以下の性質の全てを有する多能性幹細胞である、請求項1~7のいずれか1項に記載の細胞製剤:
(i)テロメラーゼ活性が低いか又は無い;
(ii)三胚葉のいずれの胚葉の細胞に分化する能力を持つ;
(iii)腫瘍性増殖を示さない;及び
(iv)セルフリニューアル能を持つ。 - 前記多能性幹細胞が、表皮角化細胞、血管内皮細胞、血管周皮細胞、脂肪細胞、脂肪前駆細胞、皮膚線維芽細胞、及び神経鞘細胞からなる群から選択される1つ以上の細胞に分化する能力を有する、請求項1~8のいずれか1項に記載の細胞製剤。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15838432.1A EP3189844B1 (en) | 2014-09-05 | 2015-06-19 | Pluripotent stem cell for treating diabetic skin ulcer |
CA2959957A CA2959957C (en) | 2014-09-05 | 2015-06-19 | Pluripotent stem cell for treating diabetic skin ulcer |
KR1020177006143A KR102136450B1 (ko) | 2014-09-05 | 2015-06-19 | 당뇨병성 피부 궤양 치료를 위한 다능성 줄기 세포 |
DK15838432.1T DK3189844T3 (da) | 2014-09-05 | 2015-06-19 | Pluripotent stamcelle til behandling af diabetisk hudsår |
KR1020187026476A KR20180104196A (ko) | 2014-09-05 | 2015-06-19 | 당뇨병성 피부 궤양 치료를 위한 다능성 줄기 세포 |
PL15838432T PL3189844T3 (pl) | 2014-09-05 | 2015-06-19 | Pluripotencjalna komórka macierzysta do leczenia cukrzycowego owrzodzenia skóry |
US15/508,872 US20170258844A1 (en) | 2014-09-05 | 2015-06-19 | Pluripotent stem cell for treating diabetic skin ulcer |
AU2015310286A AU2015310286B2 (en) | 2014-09-05 | 2015-06-19 | Pluripotent stem cell for treating diabetic skin ulcer |
CN201580047340.2A CN107073041A (zh) | 2014-09-05 | 2015-06-19 | 糖尿病性皮肤溃疡治疗的多功能性干细胞 |
SG11201701788YA SG11201701788YA (en) | 2014-09-05 | 2015-06-19 | Pluripotent stem cell for treating diabetic skin ulcer |
ES15838432T ES2846795T3 (es) | 2014-09-05 | 2015-06-19 | Células madres pluripotentes para el tratamiento de la úlcera cutánea diabética |
US16/288,705 US11000552B2 (en) | 2014-09-05 | 2019-02-28 | Pluripotent stem cell for treating diabetic skin ulcer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014181463A JP6452107B2 (ja) | 2014-09-05 | 2014-09-05 | 糖尿病性皮膚潰瘍治療のための多能性幹細胞 |
JP2014-181463 | 2014-09-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/508,872 A-371-Of-International US20170258844A1 (en) | 2014-09-05 | 2015-06-19 | Pluripotent stem cell for treating diabetic skin ulcer |
US16/288,705 Division US11000552B2 (en) | 2014-09-05 | 2019-02-28 | Pluripotent stem cell for treating diabetic skin ulcer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016035419A1 true WO2016035419A1 (ja) | 2016-03-10 |
Family
ID=55439490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/067789 WO2016035419A1 (ja) | 2014-09-05 | 2015-06-19 | 糖尿病性皮膚潰瘍治療のための多能性幹細胞 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20170258844A1 (ja) |
EP (1) | EP3189844B1 (ja) |
JP (1) | JP6452107B2 (ja) |
KR (2) | KR20180104196A (ja) |
CN (1) | CN107073041A (ja) |
AU (1) | AU2015310286B2 (ja) |
CA (1) | CA2959957C (ja) |
DK (1) | DK3189844T3 (ja) |
ES (1) | ES2846795T3 (ja) |
HU (1) | HUE052584T2 (ja) |
PL (1) | PL3189844T3 (ja) |
PT (1) | PT3189844T (ja) |
SG (1) | SG11201701788YA (ja) |
WO (1) | WO2016035419A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110831607A (zh) * | 2017-06-19 | 2020-02-21 | 国立大学法人北海道大学 | 大疱性表皮松解症的治疗剂 |
EP3492091A4 (en) * | 2016-07-29 | 2020-02-26 | Tohoku University | PROPHYLACTIC OR THERAPEUTIC AGENT FOR VASCULAR DISORDER |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6452107B2 (ja) | 2014-09-05 | 2019-01-16 | 国立大学法人 東京大学 | 糖尿病性皮膚潰瘍治療のための多能性幹細胞 |
US20200237828A1 (en) * | 2017-10-17 | 2020-07-30 | Hiroshima University | Pluripotent stem cells inducing osteochondral repair |
EP3773481A4 (en) * | 2018-03-27 | 2022-01-05 | Tautona Group IP Holding Company, L.L.C. | TOPICAL AND TRANSDERMAL ADMINISTRATION OF AN IRON CHELATOR TO PREVENT AND TREAT CHRONIC WOUNDS |
CN110585242A (zh) * | 2019-10-15 | 2019-12-20 | 南通大学 | 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法 |
KR20210127510A (ko) | 2020-04-14 | 2021-10-22 | 사회복지법인 삼성생명공익재단 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 당뇨병성 피부질환 예방 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133943A1 (ja) * | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 生体内機能的細胞の高効率採取法 |
JP2010505849A (ja) * | 2006-10-06 | 2010-02-25 | ユニバーシティ オブ バージニア パテント ファウンデーション | 糖尿病性創傷治癒に有用な方法および組成物 |
WO2011007900A1 (ja) * | 2009-07-15 | 2011-01-20 | Dezawa Mari | 生体組織から単離できる多能性幹細胞 |
WO2013082543A1 (en) * | 2011-11-30 | 2013-06-06 | Advanced Cell Technology, Inc. | Mesenchymal stromal cells and uses related thereto |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3461884A1 (en) | 2004-03-22 | 2019-04-03 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
CN101864392B (zh) | 2005-12-13 | 2016-03-23 | 国立大学法人京都大学 | 核重新编程因子 |
KR20200124766A (ko) * | 2006-10-02 | 2020-11-03 | 메조블라스트 인터내셔널 에스에이알엘 | 중간엽 줄기 세포 및 그에 대한 용도 |
DK2055308T3 (en) * | 2006-10-30 | 2017-07-17 | Genomix Co Ltd | PHARMACEUTICALS FOR PROMOTING FUNCTIONAL REGENERATION OF DAMAGED TISSUE |
WO2008100442A1 (en) * | 2007-02-09 | 2008-08-21 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
JP2014133703A (ja) * | 2011-03-30 | 2014-07-24 | Clio Inc | 生体組織から単離できるssea−3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物 |
US9399758B2 (en) * | 2009-07-15 | 2016-07-26 | Mari Dezawa | SSEA3(+) pluripotent stem cell that can be isolated from body tissue |
US20130251670A1 (en) * | 2011-09-13 | 2013-09-26 | Aidan Products, Inc | Treatment of Macular Edema Utilizing Stem Cell and Conditioned Media Thereof |
WO2013131192A1 (en) * | 2012-03-06 | 2013-09-12 | Aris Aziz | Placental stem cells, methods for isolating same and use thereof |
WO2013188679A1 (en) * | 2012-06-13 | 2013-12-19 | Stemgent, Inc. | Methods of preparing pluripotent stem cells |
WO2014027474A1 (ja) * | 2012-08-17 | 2014-02-20 | 株式会社Clio | 心筋梗塞の修復再生を誘導する多能性幹細胞 |
WO2014133090A1 (ja) * | 2013-02-28 | 2014-09-04 | 国立大学法人浜松医科大学 | 脳腫瘍治療のための多能性幹細胞 |
CN105188754B (zh) * | 2013-03-01 | 2019-11-26 | 株式会社Clio | 含有将多能干细胞诱导至损伤部位的迁移因子的药物组合物 |
JP6452107B2 (ja) | 2014-09-05 | 2019-01-16 | 国立大学法人 東京大学 | 糖尿病性皮膚潰瘍治療のための多能性幹細胞 |
-
2014
- 2014-09-05 JP JP2014181463A patent/JP6452107B2/ja active Active
-
2015
- 2015-06-19 KR KR1020187026476A patent/KR20180104196A/ko active Application Filing
- 2015-06-19 US US15/508,872 patent/US20170258844A1/en not_active Abandoned
- 2015-06-19 HU HUE15838432A patent/HUE052584T2/hu unknown
- 2015-06-19 EP EP15838432.1A patent/EP3189844B1/en active Active
- 2015-06-19 PT PT158384321T patent/PT3189844T/pt unknown
- 2015-06-19 DK DK15838432.1T patent/DK3189844T3/da active
- 2015-06-19 PL PL15838432T patent/PL3189844T3/pl unknown
- 2015-06-19 CN CN201580047340.2A patent/CN107073041A/zh active Pending
- 2015-06-19 CA CA2959957A patent/CA2959957C/en active Active
- 2015-06-19 AU AU2015310286A patent/AU2015310286B2/en not_active Ceased
- 2015-06-19 WO PCT/JP2015/067789 patent/WO2016035419A1/ja active Application Filing
- 2015-06-19 SG SG11201701788YA patent/SG11201701788YA/en unknown
- 2015-06-19 KR KR1020177006143A patent/KR102136450B1/ko active IP Right Grant
- 2015-06-19 ES ES15838432T patent/ES2846795T3/es active Active
-
2019
- 2019-02-28 US US16/288,705 patent/US11000552B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505849A (ja) * | 2006-10-06 | 2010-02-25 | ユニバーシティ オブ バージニア パテント ファウンデーション | 糖尿病性創傷治癒に有用な方法および組成物 |
WO2009133943A1 (ja) * | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 生体内機能的細胞の高効率採取法 |
WO2011007900A1 (ja) * | 2009-07-15 | 2011-01-20 | Dezawa Mari | 生体組織から単離できる多能性幹細胞 |
WO2013082543A1 (en) * | 2011-11-30 | 2013-06-06 | Advanced Cell Technology, Inc. | Mesenchymal stromal cells and uses related thereto |
Non-Patent Citations (5)
Title |
---|
KURODA,Y. ET AL.: "Unique multipotent cells in adult human mesenchymal cell populations", PROC. NATL. ACAD. SCI. USA, vol. 107, no. 19, 2010, pages 8639 - 8643, XP008152782, DOI: doi:10.1073/pnas.0911647107 * |
MARI DEZAWA: "Saisei Iryo Kenkyu no Genjo to Muse Saibo no Shorai Tenbo", HEISEI 26 NENDO SENTAN GIJUTSU KENSHU SLIDE, 20 June 2014 (2014-06-20), XP009502646 * |
MARI DEZAWA: "Seitai Yurai no Kan'yokei Soshiki ni Naiho sareru Muse Saibo no Hakken", EXPERIMENTAL MEDICINE, vol. 29, no. 19, 2011, pages 3077 - 3084, XP008178634 * |
NORIYUKI AOI ET AL.: "Aratana Master Kansaibo (MUSE Saibo) no Riyo ni Mukete", DAI 20 KAI JAPAN SOCIETY OF PLASTIC AND RECONSTRUCTIVE SURGERY KISO GAKUJUTSU SHUKAI PROGRAM, 2011, Shorokushu, pages 95, XP009500877 * |
See also references of EP3189844A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3492091A4 (en) * | 2016-07-29 | 2020-02-26 | Tohoku University | PROPHYLACTIC OR THERAPEUTIC AGENT FOR VASCULAR DISORDER |
US11419899B2 (en) | 2016-07-29 | 2022-08-23 | Tohoku University | Method of treating aortic aneurysm using muse cells |
CN110831607A (zh) * | 2017-06-19 | 2020-02-21 | 国立大学法人北海道大学 | 大疱性表皮松解症的治疗剂 |
Also Published As
Publication number | Publication date |
---|---|
PL3189844T3 (pl) | 2021-06-28 |
AU2015310286A1 (en) | 2017-03-23 |
US11000552B2 (en) | 2021-05-11 |
HUE052584T2 (hu) | 2022-03-28 |
PT3189844T (pt) | 2021-02-05 |
KR102136450B1 (ko) | 2020-07-21 |
EP3189844A4 (en) | 2018-05-02 |
CN107073041A (zh) | 2017-08-18 |
JP6452107B2 (ja) | 2019-01-16 |
US20190192574A1 (en) | 2019-06-27 |
AU2015310286B2 (en) | 2018-11-08 |
EP3189844A1 (en) | 2017-07-12 |
KR20180104196A (ko) | 2018-09-19 |
SG11201701788YA (en) | 2017-06-29 |
CA2959957A1 (en) | 2016-03-10 |
CA2959957C (en) | 2020-12-15 |
DK3189844T3 (da) | 2021-01-18 |
US20170258844A1 (en) | 2017-09-14 |
KR20170055477A (ko) | 2017-05-19 |
ES2846795T3 (es) | 2021-07-29 |
JP2016056109A (ja) | 2016-04-21 |
EP3189844B1 (en) | 2020-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6452107B2 (ja) | 糖尿病性皮膚潰瘍治療のための多能性幹細胞 | |
Shi et al. | Localization of human adipose-derived stem cells and their effect in repair of diabetic foot ulcers in rats | |
Lin et al. | Evaluation of a multi-layer adipose-derived stem cell sheet in a full-thickness wound healing model | |
Azari et al. | Effects of transplanted mesenchymal stem cells isolated from Wharton’s jelly of caprine umbilical cord on cutaneous wound healing; histopathological evaluation | |
Martin et al. | Enhancing repair of full-thickness excisional wounds in a murine model: impact of tissue-engineered biological dressings featuring human differentiated adipocytes | |
KR102590455B1 (ko) | 주산기 조직 유래된 중간엽 줄기 세포: 그의 제조 방법 및 용도 | |
Xiang et al. | Direct in vivo application of induced pluripotent stem cells is feasible and can be safe | |
JP2020172536A (ja) | 創傷治癒のための幹細胞 | |
Arjunan et al. | Inhibition of growth of Asian keloid cells with human umbilical cord Wharton’s jelly stem cell-conditioned medium | |
KR20200016298A (ko) | 표피 수포증 치료제 | |
JP2015160820A (ja) | 慢性腎障害治療のための多能性幹細胞 | |
WO2018021515A1 (ja) | 血管障害の予防又は治療剤 | |
JP5845089B2 (ja) | 肢虚血の治療 | |
JP7072777B2 (ja) | 慢性腎障害治療のための多能性幹細胞 | |
Lai et al. | Combination of PDGF-BB and adipose-derived stem cells accelerated wound healing through modulating PTEN/AKT pathway | |
KR101617673B1 (ko) | 성체줄기세포 및 엘라스틴 유사 폴리펩타이드를 포함하는 상처 치료 촉진용 약학적 조성물 | |
JP7473207B2 (ja) | 末梢血流障害の治療剤 | |
KR20230137808A (ko) | 지방 조직 유래 중간엽 줄기세포 및 인간 기질 혈관 분획을 포함하는 혈관신생 촉진용 조성물 | |
JP2021073305A (ja) | 慢性腎障害治療のための多能性幹細胞 | |
Al-Fouadi | Wound Healing Potential of Human Neonatal Mesenchymal Cells in an Animal Model of Hyperglycemia | |
Zhang | The Use of Cell-based Approaches for Inducing Therapeutic Vascularization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15838432 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2959957 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15508872 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015310286 Country of ref document: AU Date of ref document: 20150619 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015838432 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015838432 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201701788Y Country of ref document: SG |